Regulatory chaos: How conflicting interpretations of breast implants are undermining the FDA’s reputation
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Apr-2025 00:08 ET (30-Apr-2025 04:08 GMT/UTC)
A new Reichman University study examines how conflicting interpretations regarding breast implants risk the erosion of the reputation of the US Food and Drug Administration (FDA). The FDA frequently finds itself embroiled in public debates about the severity of side effects associated with drugs or medical devices it has approved. These debates typically generate differing viewpoints among the medical community, patients, and the general public, with some arguing that very serious side effects warrant significant regulatory intervention and others maintaining that such intervention is unnecessary.
Natural killer (NK) cells are key innate immune lymphocytes, which play important roles against tumors. However, tumor-infiltrating NK cells are always hypofunctional/exhaustive. On the one hand, this state is contributed by context-dependent interactions between inhibitory NK cell checkpoint receptors and their ligands, which usually vary in different tumor types and stages during tumor development. On the other hand, the inhibitory functions of intracellular checkpoint molecules of NK cells are more similar across different tumor types, representing common mechanisms limiting the potential of NK cell therapy. In this review, representative NK cell intracellular checkpoint molecules in different aspects of NK cell biology were reviewed, and therapeutic potentials were discussed by targeting these molecules to promote antitumor NK cell therapy.
On November 27, the prestigious journal Nature will publish the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA trial, showed that delaying and shortening the duration of a specific anti-cancer therapy (CDK4/6 inhibitors) in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes, while reducing toxicity and achieving substantial cost reductions: over 45 million euros per year in the Netherlands and over 5 billion dollars in the United States.